BOULDER, Colo.--(BUSINESS WIRE)--miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA-based therapeutics for cardiovascular and muscle disease, announced today the publication of data demonstrating the essential role of microRNA-451 (miR-451) in the regulation of erythropoiesis, the process of red blood cell production in the body. Published in the August 1 issue of the journal Genes & Development, the findings highlight miR-451 as a promising target in the development of therapies for the treatment of myeloproliferative diseases, diseases of the blood characterized by an overabundance of blood cells. The study was conducted by researchers led by Eric N. Olson, Ph.D., at the University of Texas Southwestern Medical Center. miRagen is the exclusive licensee of intellectual property rights related to this discovery.
